0
0
3/12/26 at 12:41pm
Organization
Medscape
Author
Crystal Phend
31 words
0
Comments
Apixaban halved the risk for bleeding compared with rivaroxaban in the treatment of acute venous thromboembolism in the randomized COBRRA trial.
You are the first to view
https://www.medscape.com/viewarticle/direct-oral-anticoagulants-face-vte-trial-apixaban-confirmed-2026a10007nu
Create an account
or login to join the discussion